SLN קפיטליזציה חשבונאית Silence Therapeutics plc

Silence Therapeutics (SLN) dominates the siRNA segment, developing drugs to block pathogenic genes in cardiovascular diseases via the GOLD system. The quotes provided below, recorded at 0.05, complement the business outlook, where molecule synthesis is optimized using AI and robotics. Meanwhile, the company maintains its human capital, retaining leading biochemists through a system of grants and long-term incentives.

This indicator is calculated as the difference between all assets and liabilities of the company as of the reporting date. This metric reflects the value of net assets, protecting the investor from overpaying due to unjustified market optimism. For Silence Therapeutics (SLN), whose success depends on clinical trials of RNA drugs rather than economic cycles, this parameter is critically important. The current value of 0.05 demonstrates the real financial foundation of the business. The dynamics of the organization's balance sheet capital on the GURU.Markets platform allow for an assessment of the issuer's stability.